Top Pharma and Life Sciences CFO Executive Search Firms in New York

Opening accounting case

The partner confirms a milestone, operations books the cash and finance has not established the performance obligation

Give finalists a fictional collaboration containing a licence, research services, joint governance, variable milestones, cost sharing and royalties. Add a scientific event, disputed acceptance language, an invoice not yet issued and a board forecast that treats the amount as available cash.

Ask candidates to separate scientific achievement, contractual right, accounting recognition, tax, collection and disclosure with legal, alliance and technical accounting advisers. Then reveal that changing the board forecast reduces runway below the planned readout.

Strong CFOs correct the bridge, preserve the accounting process and bring the capital consequence forward. They do not give a snap technical conclusion from an interview packet or allow headline deal value to become revenue because the company needs it.

Mandate selection

Choose whether capital formation, public control, portfolio finance, collaboration economics or launch leads

A celebrated capital-markets CFO may not be the controller-remediation leader, and a technical accountant may lack portfolio or investor judgment. Name the dominant decision and transfer gap for every finalist.

Runway case

The forecast shows eighteen months of cash and the lead readout moves beyond every financeable option

Give candidates a monthly decision calendar, trial and CMC commitments, financing assumptions, minimum cash, collaboration receipts and downside levers. Ask when the company acts and which programme changes under delay, weak data or closed markets.

Then reveal that the largest reduction would damage the lead programme's interpretability. Strong judgment protects the critical proof, distinguishes reversible and irreversible spend, and gives the board an earlier trigger. A runway month without a decision path is not enough.

Accrual case

Clinical operations estimates patient activity while three vendors use incompatible cut-off evidence

Ask finalists to map contracts, visits, monitoring, pass-through costs, amendments, data services, invoices and close timing. Then disclose a recurring true-up large enough to affect the public burn narrative.

The candidate should establish source ownership, estimation method, review precision, retrospective testing and escalation. The best answer improves both operational forecasting and financial reporting without asking the clinical team to manufacture false certainty.

Control-remediation case

A material close review depends on the CFO's memory and produces no evidence another reviewer can inspect

Give finalists risk, population, review steps, system reports, exceptions, filing calendar and constrained staff. Ask for interim assurance, documentation, competence, segregation, testing and durable redesign.

Then reveal an upcoming financing that makes delay costly. Strong candidates protect the control and disclosure conclusion, explain residual risk to the audit committee and sequence remediation. They do not sign because the final number appears reasonable.

Financing case

An at-the-market option preserves flexibility and could signal weakness before the pivotal result

Give candidates cash needs, market liquidity, disclosure status, programme alternatives, investor concentration, covenant context and a binary event. Ask for amount, timing, controls, communication, downside and alternatives with qualified securities advisers.

Then make the clinical team request another cohort that moves the event. Strong candidates integrate evidence need and capital access without pressuring science to fit a financing calendar. Score option preservation and assumption clarity, not whether the candidate always raises early or late.

Going-concern case

The base plan supports twelve months only if a financing without committed terms is treated as probable

Give finalists liquidity, contractual obligations, clinical and CMC commitments, realistic cost actions, board plans, financing history and an audit timetable. Ask how management assesses conditions, plans and evidence; what reaches the audit committee; and how forecast, disclosure and financing communication remain aligned with qualified accounting and securities advisers.

Then reveal that the strongest cost action would end the programme most likely to attract capital. Strong candidates do not solve the issue by increasing financing probability or by cutting indiscriminately. They build executable alternatives, identify decision dates and show which actions are within the company's control.

Score whether the candidate distinguishes a survival plan from a valuation plan. The accounting conclusion belongs to the company's facts and advisers, not an interview answer, but the CFO must create evidence early enough that governance can still act.

Transaction case

The acquisition adds a promising in-process programme and removes the people who understand its cost and controls

Give candidates an invented purchase agreement, asset evidence, contingent payments, integration plan, systems, tax structure, control gaps and a team-retention problem. Ask how finance sequences valuation, accounting, disclosure, treasury, tax, controls and operating integration without taking authority from scientific and quality leaders.

Then disclose a contrary manufacturing assumption after signing. A credible CFO preserves independent valuation and accounting, updates scenarios, escalates disclosure and impairment questions with qualified advisers, and prevents deal advocacy from becoming the control environment.

The exercise tests post-transaction courage as much as transaction experience. Boards should ask for a case where the CFO changed integration economics after new evidence, not only a completed deal list. References can verify the governance without revealing purchase price allocation or confidential programme data.

Firm diligence

Ask the proposed partner to prove finance calibration beyond a list of completed biotech offerings

Observer network

Use six references because finance truth lives across science, contracts, quality and governance

Use candidate consent and bounded questions. Exclude company identity where necessary, contract terms, nonpublic forecasts, clinical results and securities information.

Audit-committee answers

Questions directors and CEOs ask during a New York life sciences CFO appointment

Reciprocal evidence room

Open finance diligence by tracing one asset through work performed, accrual, forecast, financing and disclosure

Provide controlled evidence on cash scenarios, programme commitments, trial and manufacturing accruals, collaboration rights, revenue and R&D policies, close, internal and disclosure controls, audit issues, tax, treasury, capital alternatives, launch economics, team depth and board reporting.

Unknowns need owners and ranges. The finalist should see material control weaknesses, financing dependencies and forecast assumptions before appointment without receiving unnecessary patient data or tradable information.

Complete identity, conflicts, references, equity, compensation and reciprocal diligence before appointment. Candidates should not advise on a live accounting, audit, financing or disclosure decision.

First committee cycle

Require eight evidence-to-cash truths before approving the next financing narrative

The appointment is working when finance exposes the scientific and contractual assumptions before they become a board number.